Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zithromax™ · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Zithromax™ (azithromycin) 500mg tablets | DRUG | - |
| Endoscopic Sinus Surgery | PROCEDURE | - |
| Blood sampling for hematology | PROCEDURE | - |
| Blood sampling for plasma chemistry profile | PROCEDURE | - |
| Serum pregnancy test (for women of child-bearing potential) | PROCEDURE | - |
Inclusion Criteria: * Subjects considered by the Principal Investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (OMC). Exclusion Criteria: * Known or suspected hypersensitivity...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Optinose US Inc. | OPTN | 1 | PHASE3 | OPN-375 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | dupilumab |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Dupilumab |
Zithromax is an antibiotic studied for sinusitis, an infection or inflammation of the nasal sinuses. It is a small molecule medicine developed by Pfizer. The sinusitis research program is at Phase 2, and the drug is also widely known by its generic name, azithromycin.
Zithromax is developed and marketed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company behind the Zithromax brand, including the 500mg tablet form referenced in its sinusitis research.
Zithromax is in Phase 2 development for sinusitis. One Phase 2 trial in the sinusitis program has been completed, and no trials in that program are currently active. The completed study enrolled 72 participants and was conducted in the United States.
The sinusitis program includes one completed Phase 2 trial, NCT00232154, titled a study to measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets. It enrolled 72 adults aged 18 and older in the United States and was randomized but uncontrolled.
Yes. Zithromax is the brand name for azithromycin, and the product is also described as Zithromax 500mg tablets. People searching for azithromycin sinusitis information are looking at the same medicine that Pfizer develops and sells under the Zithromax brand name.
Zithromax is a small molecule antibiotic. Its sinusitis research measured drug levels in nasal tissue and blood after a single 2g dose or 500mg tablets, reflecting the goal of delivering the medicine to the infected sinus tissue where it acts against the bacteria causing the infection.